Kos Biotechnology Partners, a life sciences investment firm, has successfully closed its inaugural global fund, reaching $123 million in total capital commitments. Launched in December 2025, this fund is notable as the first life sciences-focused investment vehicle in Greece and the country’s largest venture capital fund to date. Founded by Dr. Simos Simeonidis and Alex Tzoukas, Kos aims to connect the U.S. biopharma ecosystem with European innovations, investing across all development stages in sectors like biotechnology and technology-enabled healthcare. The firm has already completed two investments and is poised to make more later this year.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://pulse2.com/kos-biotechnology-partners-announces-third-fund-closing-at-123-million/
